Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) + paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)

Abstract

3054

Laurie SA; Arnold A; Gauthier I; Chen E; Goss G; Ellis P; Shepherd FA; Matthews S; Robertson J; Seymour L

Journal of Clinical Oncology, Vol. 24, No. 18_suppl, pp. 3054–3054

American Society of Clinical Oncology (ASCO)

June 20, 2006

10.1200/jco.2006.24.18_suppl.3054

0732-183X

Andrew Arnold

Peter Ellis